National Institute of Health Grant Application


 

TIDMHML 
 
RNS Number : 0832U 
Henderson Morley PLC 
18 June 2009 
 
18 June 2009 
 
HENDERSON MORLEY PLC 
(AIM: HML) 
("Henderson Morley" or "the Company") 
 
National Institute of Health Grant Application 
 
The Board of Henderson Morley, the AIM quoted biotechnology company, is pleased 
to announce that further to previous announcements regarding the Company's 
Collaborative Research Agreement with the Australian Centre for Vaccine 
Development ("ACVD"), a joint grant application is being written for submission 
to the US government funded National Institute of Health ("NIH"). 
 
The joint grant application will be submitted with the goal of securing funding 
to further develop the Cytomegalovirus ("CMV") Vaccine candidate (part of the 
PREPS and L-particles vaccine platform). 
 
The NIH has announced a "Request for Applications" ("RFA") specifically in the 
field of vaccines against diseases considered to be of significant importance, 
and the NIH has specifically highlighted CMV. The research goals of this RFA are 
to "To facilitate the development and testing of candidate vaccines". Henderson 
Morley has engaged a professional US based grant writing company to advise on 
available grant budgets and to prepare and submit the grant application. 
 
The grant application will be written with the goal of undertaking further 
research studies for a more rapid development of Henderson Morley's vaccine 
candidate. The grant has to be submitted to the NIH prior to their deadline of 
27th July 2009, and may be up to US $500,000 per year for up to five years. 
 
Professor Rajiv Khanna the Director of the ACVD will be partnering the 
application. He has successfully applied for grant funding from the NIH in the 
past. 
 
Commenting, Prof Khanna stated:  "I am very pleased to be collaborating with 
Henderson Morley on this NIH grant proposal. CMV has been recognised by the NIH 
as an important pathogen with potential for a protective vaccine. I was 
approached by the NIH and invited to make an application under this RFA as they 
were aware of my research." 
 
Andrew Knight, Chairman of Henderson Morley, commented: "The Company is 
exploring a number of avenues for securing non-dilutive funding for our research 
projects. We anticipate that this will be the first of several grant proposals 
to be made to the NIH and elsewhere. We are very pleased to be working on this 
proposal with Prof Khanna as his prior experience will be invaluable". 
 
=-END-- 
 
 
ENQUIRIES: 
 
HENDERSON MORLEY PLC                                                   0121 442 
4600 
Andrew Knight, Chairman 
 
BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350 
(Public Relations) 
Maxine Barnes 
 Gemma O'Hara 
 
BREWIN DOLPHIN INVESTMENT BANKING                                    0113 241 
0126 
(Nominated Adviser) 
Neil Baldwin 
 
RIVINGTON STREET CORPORATE FINANCE LTD                            020 7562 3380 
(Broker) 
Monisha Varadan 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 STRBLGDLSSBGGCR

Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024